Zobrazeno 1 - 10
of 245
pro vyhledávání: '"Tanja D de Gruijl"'
Publikováno v:
PLoS ONE, Vol 12, Iss 7, p e0180333 (2017)
Antigen exposure to oral mucosa is generally thought to lead to immune tolerance induction. However, very little is known about the subset composition and function of dendritic cells (DC) migrating from human oral mucosa. Here we show that migratory
Externí odkaz:
https://doaj.org/article/fc4018798294469fb51efc3ea5dbb96f
Autor:
John Pradeep Veluchamy, Jan Spanholtz, Marleen Tordoir, Victor L Thijssen, Daniëlle A M Heideman, Henk M W Verheul, Tanja D de Gruijl, Hans J van der Vliet
Publikováno v:
PLoS ONE, Vol 11, Iss 6, p e0157830 (2016)
The ability of Natural Killer (NK) cells to kill tumor targets has been extensively studied in various hematological malignancies. However, NK cell therapy directed against solid tumors is still in early development. Epidermal Growth Factor Receptor
Externí odkaz:
https://doaj.org/article/a994ac3f171142b6b452ccff5a5569c6
Autor:
Cynthia M Fehres, Sven C M Bruijns, Brigit N Sotthewes, Hakan Kalay, Lana Schaffer, Steven R Head, Tanja D de Gruijl, Juan J Garcia-Vallejo, Yvette van Kooyk
Publikováno v:
PLoS ONE, Vol 10, Iss 11, p e0143519 (2015)
Cutaneous antigen presenting cells (APCs) are critical for the induction and regulation of skin immune responses. The human skin contains phenotypically and functionally distinct APCs subsets that are present at two separated locations. While CD1ahig
Externí odkaz:
https://doaj.org/article/e0abe833e11e4e60a875e4ad24780fa5
Autor:
Jurjen M Ruben, Lindy L Visser, Kimberley M Heinhuis, Tom O'Toole, Hetty J Bontkes, Theresia M Westers, Gert J Ossenkoppele, Tanja D de Gruijl, Arjan A van de Loosdrecht
Publikováno v:
PLoS ONE, Vol 10, Iss 8, p e0135219 (2015)
The CD34+ MUTZ-3 acute myeloid leukemia cell line has been used as a dendritic cell (DC) differentiation model. This cell line can be cultured into Langerhans cell (LC) or interstitial DC-like cells using the same cytokine cocktails used for the diff
Externí odkaz:
https://doaj.org/article/d046874fbf094a359805baa86be3c4d3
Autor:
Jelle J Lindenberg, Dinja Oosterhoff, Claudia C Sombroek, Sinéad M Lougheed, Erik Hooijberg, Anita G M Stam, Saskia J A M Santegoets, Henk J Tijssen, Jan Buter, Herbert M Pinedo, Alfons J M van den Eertwegh, Rik J Scheper, Hans J P M Koenen, Rieneke van de Ven, Tanja D de Gruijl
Publikováno v:
PLoS ONE, Vol 8, Iss 7, p e70237 (2013)
In cancer patients pervasive systemic suppression of Dendritic Cell (DC) differentiation and maturation can hinder vaccination efficacy. In this study we have extensively characterized migratory DC subsets from human skin and studied how their migrat
Externí odkaz:
https://doaj.org/article/e9d9d82e42794b9fa4ba094021b7285f
Autor:
Kristina Lundberg, Ann-Sofie Albrekt, Inge Nelissen, Saskia Santegoets, Tanja D de Gruijl, Sue Gibbs, Malin Lindstedt
Publikováno v:
PLoS ONE, Vol 8, Iss 1, p e52875 (2013)
BACKGROUND: Dendritic cells (DCs) comprise heterogeneous populations of cells, which act as central orchestrators of the immune response. Applicability of primary DCs is restricted due to their scarcity and therefore DC models are commonly employed i
Externí odkaz:
https://doaj.org/article/8ae56581e1a24372a42a4975bc38c0ea
Autor:
Richard van Hillegersberg, Tom van den Ende, Sybren L. Meijer, Rob H.A. Verhoeven, Max Nieuwdorp, Mark P. G. Dings, Nadia Haj Mohammad, Tanja D. de Gruijl, Nicolien C. de Clercq, H.W.M. van Laarhoven, Jacques J. Bergman, Elisabeth D. Geijsen, Stella Mook, Sandor Schokker, Maarten C.C.M. Hulshof, Nicole C.T. van Grieken, Maarten F. Bijlsma, Bauke Ylstra, Jelle P. Ruurda, Mark I. van Berge Henegouwen, Suzanne S. Gisbertz, Tanya T.D. Soeratram
Publikováno v:
van den Ende, T, Clercq, N D, van Berge Henegouwen, M I, Gisbertz, S S, Geijsen, D, Verhoeven, R, Meijer, S L, Schokker, S, Dings, M, Bergman, J J G H M, Haj Mohammad, N, Ruurda, J P, van Hillegersberg, R, Mook, S, Nieuwdorp, M, de Gruijl, T D, Soeratram, T T D, Ylstra, B, van Grieken, N C T, Bijlsma, M F, Hulshof, M C C M & van Laarhoven, H W 2021, ' Neoadjuvant Chemoradiotherapy Combined with Atezolizumab for Resectable Esophageal Adenocarcinoma : A Single Arm Phase II Feasibility Trial (PERFECT) ', Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 27, no. 12, pp. 3351-3359 . https://doi.org/10.1158/1078-0432.CCR-20-4443
Clinical cancer research : an official journal of the American Association for Cancer Research, 27(12), 3351-3359. American Association for Cancer Research Inc.
Clinical cancer research, 27(12), 3351-3359. American Association for Cancer Research Inc.
Clin Cancer Res
Clinical cancer research : an official journal of the American Association for Cancer Research, 27(12), 3351-3359. American Association for Cancer Research Inc.
Clinical cancer research, 27(12), 3351-3359. American Association for Cancer Research Inc.
Clin Cancer Res
Purpose: The CROSS trial established neoadjuvant chemoradiotherapy (nCRT) for patients with resectable esophageal adenocarcinoma (rEAC). In the PERFECT trial, we investigated the feasibility and efficacy of nCRT combined with programmed-death ligand-
Autor:
Arjan W. Griffioen, Peter Timmerman, Ruben S. A. Goedegebuure, Hans J. van der Vliet, Tanja D. de Gruijl, Henk M.W. Verheul, Madelon Q. Wentink
Publikováno v:
Oncologist, 26, 2, pp. e218-e229
Goedegebuure, R S A, Wentink, M Q, van der Vliet, H J, Timmerman, P, Griffioen, A W, de Gruijl, T D & Verheul, H M W 2021, ' A Phase I Open-Label Clinical Trial Evaluating the Therapeutic Vaccine hVEGF26–104/RFASE in Patients with Advanced Solid Malignancies ', Oncologist, vol. 26, no. 2, pp. e218-e229 . https://doi.org/10.1002/onco.13576
Oncologist, 26(2), e218-e229. AlphaMed Press
Oncologist, 26, e218-e229
The Oncologist
Goedegebuure, R S A, Wentink, M Q, van der Vliet, H J, Timmerman, P, Griffioen, A W, de Gruijl, T D & Verheul, H M W 2021, ' A Phase I Open-Label Clinical Trial Evaluating the Therapeutic Vaccine hVEGF26–104/RFASE in Patients with Advanced Solid Malignancies ', Oncologist, vol. 26, no. 2, pp. e218-e229 . https://doi.org/10.1002/onco.13576
Oncologist, 26(2), e218-e229. AlphaMed Press
Oncologist, 26, e218-e229
The Oncologist
Lessons Learned The novel therapeutic vaccine hVEGF26–104/RFASE was found to be safe and well tolerated in patients with cancer. hVEGF26–104/RFASE failed to induce seroconversion against native hVEGF165 and, accordingly, neither a decrease in cir
Autor:
Nathalie van Leeuwen-Kerkhoff, Shahram Kordasti, Theresia M. Westers, Giovanni A M Povoleri, Tanja D. de Gruijl, Pino J Poddighe, Arjan A. van de Loosdrecht, Jessica A Timms
Publikováno v:
Haematologica, 107(3), 655-667. Ferrata Storti Foundation
van Leeuwen-Kerkhoff, N, Westers, T M, Poddighe, P J, Povoleri, G A M, Timms, J A, Kordasti, S, de Gruijl, T D & van de Loosdrecht, A A 2022, ' Reduced frequencies and functional impairment of dendritic cell subsets and non-classical monocytes in myelodysplastic syndromes ', Haematologica, vol. 107, no. 3, pp. 655-667 . https://doi.org/10.3324/haematol.2020.268136
van Leeuwen-Kerkhoff, N, Westers, T M, Poddighe, P J, Povoleri, G A M, Timms, J A, Kordasti, S, de Gruijl, T D & van de Loosdrecht, A A 2022, ' Reduced frequencies and functional impairment of dendritic cell subsets and non-classical monocytes in myelodysplastic syndromes ', Haematologica, vol. 107, no. 3, pp. 655-667 . https://doi.org/10.3324/haematol.2020.268136
In myelodysplastic syndromes (MDS) the immune system is involved in pathogenesis as well as in disease progression. Dendritic cells (DC) are key players of the immune system by serving as regulators of immune responses. Their function has been scarce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa5391dba937cb802184434c01c08a37
https://research.vumc.nl/en/publications/db725181-9627-4bb8-b6d6-30678dae82ff
https://research.vumc.nl/en/publications/db725181-9627-4bb8-b6d6-30678dae82ff
Autor:
Iris de Weerdt, Tanja D. de Gruijl, Jurjen M Ruben, Hans van Vliet, Mark-David Levin, Lisa A King, Roeland Lameris, Arnon P. Kater, Paul W. H. I. Parren, Renate de Boer, Jan Kloosterman
Publikováno v:
de Weerdt, I, Lameris, R, Ruben, J M, de Boer, R, Kloosterman, J, King, L A, Levin, M-D, Parren, P W H I, de Gruijl, T D, Kater, A P & van der Vliet, H J 2021, ' A bispecific single-domain antibody boosts autologous Vg9Vd2-T cell responses toward CD1d in chronic lymphocytic leukemia ', Clinical cancer research : an official journal of the American Association for Cancer Research, vol. 27, no. 6, pp. 1744-1755 . https://doi.org/10.1158/1078-0432.CCR-20-4576
Clinical cancer research : an official journal of the American Association for Cancer Research, 27(6), 1744-1755. American Association for Cancer Research Inc.
Clinical cancer research, 27(6), 1744-1755. American Association for Cancer Research Inc.
Clinical Cancer Research, 27(6), 1744-1755. AMER ASSOC CANCER RESEARCH
Clinical cancer research : an official journal of the American Association for Cancer Research, 27(6), 1744-1755. American Association for Cancer Research Inc.
Clinical cancer research, 27(6), 1744-1755. American Association for Cancer Research Inc.
Clinical Cancer Research, 27(6), 1744-1755. AMER ASSOC CANCER RESEARCH
Purpose: Although considerable progress has been made with autologous T cell–based therapy in B-cell malignancies, application in chronic lymphocytic leukemia (CLL) lags behind due to disappointing response rates as well as substantial toxicity tha